Shattuck Labs, Inc.
STTKNasdaq
$7.53
↑ +6.5%Jul 17 close · end-of-day
Price
1Y↑ +871.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$845.1M
Enterprise Value
$754.7M
P/E
—
P/S
845.1
P/B
8.8
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$1.0M
Net Income (TTM)
-$49.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-5266.4%
Net Margin
-4987.4%
ROE
-52.0%
ROIC
-768.2%
Debt / Equity
—
Net Cash
$90.4M
Return 1Y
+910.7%
Company profile
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company was incorporated in 2016 and is headquartered in Austin, Texas.
- CEO
- Taylor H. Schreiber
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- Texas
- Website
- shattucklabs.com
Earnings
STTK Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.13↓ -51.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.9M | $30.0M | $652,000.00 | $1.7M | $5.7M | $1.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$36.9M | -$45.3M | -$103.3M | -$92.0M | -$80.6M | -$51.5M |
| Net income | -$36.6M | -$45.0M | -$101.9M | -$87.3M | -$75.4M | -$48.8M |
| Diluted EPS | -$2.36 | -$1.07 | -$2.41 | -$2.05 | -$1.49 | -$0.70 |
| Operating cash flow | -$33.7M | -$57.1M | -$94.5M | -$81.2M | -$60.5M | -$39.9M |
| Free cash flow | -$34.4M | -$65.0M | -$106.1M | -$81.6M | -$60.6M | -$40.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -371.8% | -150.8% | -15848.0% | -5549.6% | -1408.3% | -5150.8% |
| Net margin | -368.5% | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $3.0M | $0.00 | $0.00 | $0.00 | $1.0M | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$23.0M | -$17.9M | -$19.6M | -$14.4M | -$13.0M | -$10.7M | -$13.4M | -$15.5M |
| Net income | -$21.6M | -$16.7M | -$18.7M | -$13.7M | -$12.5M | -$10.1M | -$12.6M | -$14.8M |
| Diluted EPS | -$0.42 | -$0.33 | -$0.37 | -$0.27 | -$0.24 | -$0.14 | -$0.05 | -$0.13 |
| Operating cash flow | -$10.9M | -$16.1M | -$17.4M | -$12.0M | -$10.4M | -$8.9M | -$8.5M | -$13.4M |
| Free cash flow | -$10.9M | -$16.1M | -$17.4M | — | — | -$9.0M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1427.1% | -597.9% | — | — | — | -1071.6% | — | — |
| Net margin | -1339.5% | -556.4% | — | — | — | -1005.6% | — | — |
Company news
Jul 20, 2026
Jun 10, 2026
Jun 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.